Adults trapped on chronic oral steroids for severe asthma face a cruel medical paradox: the medications controlling their breathing gradually destroy their bones, metabolism, and immune function. Breaking this dependency has remained one of respiratory medicine's most challenging goals, particularly for patients whose asthma resists standard biologics targeting specific inflammatory pathways.
The SUNRISE trial demonstrates that tezepelumab, which blocks thymic stromal lymphopoietin (TSLP), achieved meaningful steroid reduction in 70% of participants with oral corticosteroid-dependent asthma. Among 122 patients across 63 sites, those receiving monthly subcutaneous tezepelumab injections showed significantly greater reductions in daily oral steroid requirements compared to placebo while maintaining asthma control. The study enrolled patients requiring medium to high-dose inhaled steroids plus daily oral corticosteroids despite optimal treatment.
This represents a crucial advancement in treating the most severe asthma phenotype. TSLP sits upstream of multiple inflammatory cascades, potentially explaining tezepelumab's broad efficacy where eosinophil-targeted or IgE-targeted biologics may fail. For the estimated 5-10% of asthma patients dependent on oral steroids, this could mean escaping the devastating long-term consequences of chronic corticosteroid exposure including osteoporosis, diabetes, and infections.
However, the study terminated early after enrolling only 122 of 207 planned participants, limiting statistical power and raising questions about real-world implementation. The 74% completion rate suggests tolerability concerns merit attention. While promising for steroid-dependent patients, this remains an expensive intervention requiring careful patient selection and monitoring protocols.